Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.1500 (0.78%) ($4.9100 - $5.1800) on Wed. Nov. 28, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.43% (three month average) | RSI | 24 | Latest Price | $5.1500(0.78%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -1.1% a day on average for past five trading days. | Weekly Trend | ADAP declines -8.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) SMH(17%) GDXJ(12%) UNG(12%) JETS(11%) SHY(10%) | Factors Impacting ADAP price | ADAP will decline at least -2.715% in a week (0% probabilities). XLP(-10%) XLV(-8%) VIXM(-8%) IFRA(-7%) VXX(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.715% (StdDev 5.43%) | Hourly BBV | 0 () | Intraday Trend | 1% | | | |
|
1 - 5 Day Possible Target | $-13.98(-371.46%) | Resistance Level | $5.96 | 5 Day Moving Average | $5.34(-3.56%) | 10 Day Moving Average | $5.43(-5.16%) | 20 Day Moving Average | $5.96(-13.59%) | To recent high | -63.6% | To recent low | 0.8% | Market Cap | $796m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |